Kazano Approval History

• FDA approved: Yes (First approved January 25th, 2013)
• Brand name: Kazano
• Generic name: alogliptin and metformin
• Company: Takeda Pharmaceutical Company Limited
• Treatment for: Diabetes, Type 2

Kazano (alogliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide antihyperglycemic fixed-dose combination for the treatment of type 2 diabetes.

FDA Approval History for Kazano

Date	Article
Jan 25, 2013	Takeda Receives FDA Approval for Kazano (alogliptin and metformin) for Type 2 Diabetes
Nov 28, 2011	Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

See also...

Kazano (alogliptin and metformin) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.